Hanall Biopharma (009420) announced on the 28th that its consolidated sales for the second quarter increased by 12% compared to the same period of the previous year by 26.2 billion won. During the same period, operating profit turned to black from a loss in the previous quarter with an operating profit of KRW 700 million.
Hanall Biopharmaceuticals has maintained a solid growth of more than double digits, centering on major products such as enteritis treatment ‘Normix’, prostate cancer treatment ‘Eligard’, probiotics ‘Biotop’, and hair loss treatment ‘Hairgro’ and ‘Adamo’. have.
Recently, it is expected to contribute to increasing drug sales in the future by launching new drugs such as ‘Glucofree’ for diabetes and ‘Abcito’ for gastroesophageal reflux disease.
Hanol maintains a stable financial structure with a debt-to-equity ratio of 22% with consolidated assets of KRW 183 billion, equity of KRW 150.2 billion, and liabilities of KRW 32.8 billion as of the end of the first half. Hanol maintains a virtuous R&D cycle in which profits generated from drug sales and royalties are reinvested in R&D to generate greater profits.
Park Seung-guk, CEO of Hanall Biopharmaceuticals, said, “The growth of pharmaceutical sales is continuing in the second quarter.
Various pipelines are also proceeding smoothly. Immunovant and Harbor Biomed are developing clinical trials for HL161, an autoimmune disease treatment antibody drug, in the US and China, respectively. Immunovant started phase 3 clinical trial for HL161 myasthenia gravis in the U.S. last month, and Harbor BioMed in China for myasthenia gravis, thyroid ophthalmopathy (TED), thrombocytopenia (ITP), optic neuromyelitis (NMO), and polyneuropathy (CIPD). clinical trials are in progress.
HL036, a treatment for dry eye syndrome, is undergoing a second phase 3 clinical trial in the United States. HL186 and HL187 are immuno-oncology antibodies that target TIM-3 and TIGIT, respectively, and have now confirmed candidate antibodies and entered the non-clinical stage. Hanall Biopharma and Daewoong Pharmaceutical are jointly investing. Samsung Biologics participated as a CDMO and is in charge of cell line and CMC development and clinical sample manufacturing.
Send articles on social media
